Date: 2016-10-06
Type of information: Opening of new premises
Compound:
Company: Orchard Therapeutics (UK)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On October 6, 2016, Orchard Therapeutics announced the opening of its US operations in Foster City, California.
- Orchard is developing a global platform of ex-vivo autologous gene therapies in serious and life-threatening orphan diseases. In the United States, Orchard has collaborations with the University of California Los Angeles (UCLA) and Boston Children’s Hospital, and with leading manufacturing partners specialized in gene and cell therapy.
- Foster City will serve as headquarters for the Company’s North American subsidiary, Orchard Therapeutics North America, and will provide the central technical base for laboratory operations associated with the development and validation of manufacturing processes and analytical methods for the company’s products. Orchard’s lead program in severe combined immunodeficiency due to adenosine deaminase deficiency (“ADA-SCID”) is an advanced clinical development, with a total of 39 patients treated as of September 2016.
Financial terms:
Latest news:
Is general: Yes
